.png){kind=small}
.png){kind=small}
BackTable / Urology / Podcast / Episode #149
ESMO: Practice Changing Breakthroughs
with Dr. Rana McKay and Dr. Neeraj Agarwal
This week on BackTable Urology, urologic oncologist Dr. Bogdana Schmidt (University of Utah) hosts a discussion with medical oncology experts Dr. Rana McKay (UC San Diego) and Dr. Neeraj Agarwal (University of Utah) on recent clinical trials from bladder, kidney, and prostate cancer research presented at the 2023 European Society for Medical Oncology (ESMO) Meeting.
Be part of the conversation. Put your sponsored messaging on this episode. Learn how.
BackTable, LLC (Producer). (2024, January 30). Ep. 149 – ESMO: Practice Changing Breakthroughs [Audio podcast]. Retrieved from https://www.backtable.com
Free CME
Reflect on how this Podcast applies to your day-to-day and earn free AMA PRA Category 1 CMEs. Follow the button below to claim your credits on CMEfy.
Stay Up To Date
Follow:
Subscribe:
Sign Up:
Podcast Contributors
Dr. Rana McKay
Dr. Rana McKay is a medical oncologist and associate professor at UC San Diego Health in California.
Dr. Neeraj Agarwal
Dr. Neeraj Agarwal is a professor of medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI.
Dr. Bogdana Schmidt
Dr. Bogdana Schmidt, MD, MPH, is a urologic surgeon specializing in urologic oncology at the University of Utah in Salt Lake City, Utah.
Synopsis
First, they discuss impactful data regarding bladder cancers, specifically the CheckMate 901 and the EV-302 trials which show improvement in overall survival and promise for urothelial carcinoma patients’ quality of life. The conversation moves onto kidney-specific trials such as the LITESPARK-005, which offers improved progression-free survival for patients through the use of belzutifan. The panel rounds off by discussing the progress made in prostate-specific trials with emphasis on the EMBARK and SPLASH trials involving Lutetium therapy. Finally, the doctors discuss the trend towards personalized treatment plans based on the unique goals and health requirements of the patients.
Timestamps
00:00 - Discussion on Urothelial Carcinoma: CheckMate 901 and EV-302
11:22 - Discussion on Kidney Cancer: LITESPARK-005
23:53 - Discussion on Prostate Cancer: EMBARK
31:41 - Discussion on Prostate Cancer: SPLASH vs PSMA
36:39 - Future Directions for Lutetium Therapy for Prostate Cancer
37:50 - Closing Remarks and Future Expectations
Resources
CheckMate 901 Trial Investigators. Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.
https://www.nejm.org/doi/full/10.1056/NEJMoa2309863
LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC).
https://www.sciencedirect.com/science/article/pii/S0923753423042709
LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study.
https://www.sciencedirect.com/science/article/pii/S0923753423042345
LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.
https://pubmed.ncbi.nlm.nih.gov/37119051/
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
https://pubmed.ncbi.nlm.nih.gov/26795286/
Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.
Up Next
Articles
Topics
